401 related articles for article (PubMed ID: 33593231)
21. ADAR enzyme and miRNA story: a nucleotide that can make the difference.
Tomaselli S; Bonamassa B; Alisi A; Nobili V; Locatelli F; Gallo A
Int J Mol Sci; 2013 Nov; 14(11):22796-816. PubMed ID: 24256817
[TBL] [Abstract][Full Text] [Related]
22. When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference.
Wang Y; Liang H
Bioessays; 2018 Feb; 40(2):. PubMed ID: 29280160
[TBL] [Abstract][Full Text] [Related]
23. Regulatory factors governing adenosine-to-inosine (A-to-I) RNA editing.
Hong H; Lin JS; Chen L
Biosci Rep; 2015 Mar; 35(2):. PubMed ID: 25662729
[TBL] [Abstract][Full Text] [Related]
24. Massive A-to-I RNA editing is common across the Metazoa and correlates with dsRNA abundance.
Porath HT; Knisbacher BA; Eisenberg E; Levanon EY
Genome Biol; 2017 Oct; 18(1):185. PubMed ID: 28969707
[TBL] [Abstract][Full Text] [Related]
25. An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer.
Qi L; Song Y; Chan THM; Yang H; Lin CH; Tay DJT; Hong H; Tang SJ; Tan KT; Huang XX; Lin JS; Ng VHE; Maury JJP; Tenen DG; Chen L
Nucleic Acids Res; 2017 Oct; 45(18):10436-10451. PubMed ID: 28985428
[TBL] [Abstract][Full Text] [Related]
26. RNA editing by mammalian ADARs.
Hogg M; Paro S; Keegan LP; O'Connell MA
Adv Genet; 2011; 73():87-120. PubMed ID: 21310295
[TBL] [Abstract][Full Text] [Related]
27. Adenosine-to-inosine RNA editing: perspectives and predictions.
Hoopengardner B
Mini Rev Med Chem; 2006 Nov; 6(11):1213-6. PubMed ID: 17100632
[TBL] [Abstract][Full Text] [Related]
28. Cutting Edge: Reduced Adenosine-to-Inosine Editing of Endogenous Alu RNAs in Severe COVID-19 Disease.
Crooke PS; Tossberg JT; Porter KP; Aune TM
J Immunol; 2021 Apr; 206(8):1691-1696. PubMed ID: 33782089
[TBL] [Abstract][Full Text] [Related]
29. ALU A-to-I RNA Editing: Millions of Sites and Many Open Questions.
Schaffer AA; Levanon EY
Methods Mol Biol; 2021; 2181():149-162. PubMed ID: 32729079
[TBL] [Abstract][Full Text] [Related]
30. A genome-wide map of hyper-edited RNA reveals numerous new sites.
Porath HT; Carmi S; Levanon EY
Nat Commun; 2014 Aug; 5():4726. PubMed ID: 25158696
[TBL] [Abstract][Full Text] [Related]
31. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.
Chan TH; Lin CH; Qi L; Fei J; Li Y; Yong KJ; Liu M; Song Y; Chow RK; Ng VH; Yuan YF; Tenen DG; Guan XY; Chen L
Gut; 2014 May; 63(5):832-43. PubMed ID: 23766440
[TBL] [Abstract][Full Text] [Related]
32. Identification of exceptionally potent adenosine deaminases RNA editors from high body temperature organisms.
Avram-Shperling A; Kopel E; Twersky I; Gabay O; Ben-David A; Karako-Lampert S; Rosenthal JJC; Levanon EY; Eisenberg E; Ben-Aroya S
PLoS Genet; 2023 Mar; 19(3):e1010661. PubMed ID: 36877730
[TBL] [Abstract][Full Text] [Related]
33. Adenosine-to-Inosine RNA Editing in Health and Disease.
Gatsiou A; Vlachogiannis N; Lunella FF; Sachse M; Stellos K
Antioxid Redox Signal; 2018 Sep; 29(9):846-863. PubMed ID: 28762759
[TBL] [Abstract][Full Text] [Related]
34. Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression.
Han J; An O; Hong H; Chan THM; Song Y; Shen H; Tang SJ; Lin JS; Ng VHE; Tay DJT; Molias FB; Pitcheshwar P; Tan HQ; Yang H; Chen L
Sci Adv; 2020 Jun; 6(25):eaba5136. PubMed ID: 32596459
[TBL] [Abstract][Full Text] [Related]
35. Profiling RNA Editing in Single Cells.
Fonzino A; Pesole G; Picardi E
Methods Mol Biol; 2023; 2584():347-370. PubMed ID: 36495460
[TBL] [Abstract][Full Text] [Related]
36. Detection of A-to-I Hyper-edited RNA Sequences.
Cohen-Fultheim R; Levanon EY
Methods Mol Biol; 2021; 2181():213-227. PubMed ID: 32729083
[TBL] [Abstract][Full Text] [Related]
37. Controlling the Editor: The Many Roles of RNA-Binding Proteins in Regulating A-to-I RNA Editing.
Washburn MC; Hundley HA
Adv Exp Med Biol; 2016; 907():189-213. PubMed ID: 27256387
[TBL] [Abstract][Full Text] [Related]
38. Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation.
Yang JH; Luo X; Nie Y; Su Y; Zhao Q; Kabir K; Zhang D; Rabinovici R
Immunology; 2003 May; 109(1):15-23. PubMed ID: 12709013
[TBL] [Abstract][Full Text] [Related]
39. The dsRBP and inactive editor ADR-1 utilizes dsRNA binding to regulate A-to-I RNA editing across the C. elegans transcriptome.
Washburn MC; Kakaradov B; Sundararaman B; Wheeler E; Hoon S; Yeo GW; Hundley HA
Cell Rep; 2014 Feb; 6(4):599-607. PubMed ID: 24508457
[TBL] [Abstract][Full Text] [Related]
40. Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics.
Nakano M; Nakajima M
Pharmacol Ther; 2018 Jan; 181():13-21. PubMed ID: 28716651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
